UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology
Metrics: PDF 208 views | Full Text 993 views | ?
Meghan J. Price1, Annee D. Nguyen2, Jovita K. Byemerwa3, Jasmine Flowers4, César D. Baëta5 and C. Rory Goodwin6
1 Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA
2 Department of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
3 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27708, USA
4 Department of Neurosurgery, Associated with Duke University Medical Center, Durham, NC 27710, USA
5 Department of Epidemiology and Clinical Research, Stanford University, Stanford, CA 94305, USA
6 Department of Neurosurgery, Duke Center for Brain and Spine Metastasis and Duke Cancer Institute, Durham, NC 27710, USA
|C. Rory Goodwin,||email:||[email protected]|
Keywords: UDP-6 glucose dehydrogenase; UGDH; cancer; oncology; cancer biology
Received: August 02, 2023 Accepted: September 04, 2023 Published: September 28, 2023
UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key reaction in hormone and xenobiotic metabolism and in the production of extracellular matrix precursors. In this review, we classify UGDH as a molecular indicator of tumor progression in multiple cancer types, describe its involvement in key canonical cancer signaling pathways, and identify methods to inhibit UGDH, its substrates, and its downstream products. As such, we position UGDH as an enzyme to be exploited as a potential prognostication marker in oncology and a therapeutic target in cancer biology.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.